Vantictumab, formerly labeled as OMP18R5, represents a novel monoclonal agent designed for specifically block bone associated molecule 18R5. Such approach is actively evaluated by the company in possible applications https://bookmark-dofollow.com/story28081684/vantictumab-a-deep-dive-into-this-engineered-immune-agent